{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059071","form_type":"8-K","ticker":null,"cik":"0001971543","company_name":"Mural Oncology plc","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.339257+00:00","generated_at":"2026-06-02T01:23:56.921048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mural Oncology Q1 2024 net loss $30.9M, cash runway into Q4 2025 reaffirmed","bullets":["Net loss $30.9M improved from $46.5M Q1 2023; R&D spend $26.9M down 33% YoY.","Cash, equivalents & marketable securities $231.7M as of March 31, 2024.","Nemvaleukin alfa registrational trials on track; ARTISTRY-7 interim OS data Q1 2025.","Less-frequent IV dosing trial for cutaneous melanoma enrolling; preliminary data H1 2025.","IL-18/IL-12 preclinical data presented at AACR; candidate nominations expected by end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059071","json":"https://secwatch.observer/filing/0000950170-24-059071.json","markdown":"https://secwatch.observer/filing/0000950170-24-059071.md","text":"https://secwatch.observer/filing/0000950170-24-059071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971543/000095017024059071/0000950170-24-059071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971543/000095017024059071/mura-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:23:56.921048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a8df5f64f7de1e3054db2717615b88837bbc62a9","claim":"Mural Oncology plc reported first quarter of 2024 results: net income Net loss was $30.9 million. Guidance reaffirmed.","evidence_excerpt":"Mural Oncology plc (the \"Company\") issued a press release announcing the Company’s financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017024059071/0000950170-24-059071-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Net income","value":"Net loss was $30.9 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}